Candel Therapeutics (CADL) Assets Average (2021 - 2025)
Candel Therapeutics (CADL) posted Assets Average of $109.4 million for Q4 2025, up 9.63% sequentially from $99.8 million in Q3 2025, and up 70.42% YoY from $64.2 million in Q4 2024.
Candel Therapeutics (CADL) Assets Average (2021 - 2025) Analysis & Trends
Candel Therapeutics has reported Assets Average for 5 years, with the latest figure at $109.4 million in Q4 2025.
- Quarterly Assets Average rose 70.42% year-over-year to $109.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $109.4 million (up 70.42% YoY) and the FY2025 annual result came in at $116.0 million, up 56.73% from the prior year.
- Assets Average rose to $109.4 million in Q4 2025 per CADL's latest filing, from $99.8 million in the prior quarter.
- Over five years, Assets Average peaked at $109.4 million in Q4 2025 and troughed at $24.0 million in Q3 2024.
- A 5-year average of $73.3 million and a median of $76.9 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average slumped 55.87% in 2024, then soared 315.75% in 2025.
- Over 5 years, Assets Average stood at $92.6 million in 2021, then fell by 12.13% to $81.3 million in 2022, then sank by 43.91% to $45.6 million in 2023, then soared by 40.68% to $64.2 million in 2024, then surged by 70.42% to $109.4 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $109.4 million, $99.8 million, and $100.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 109.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 109.40 Mn |
| Sep 30, 2025 | 99.78 Mn |
| Jun 30, 2025 | 100.94 Mn |
| Mar 31, 2025 | 101.39 Mn |
| Dec 31, 2024 | 64.19 Mn |
| Sep 30, 2024 | 24.00 Mn |
| Jun 30, 2024 | 28.85 Mn |
| Mar 31, 2024 | 36.21 Mn |
| Dec 31, 2023 | 45.63 Mn |
| Sep 30, 2023 | 54.38 Mn |
| Jun 30, 2023 | 62.97 Mn |
| Mar 31, 2023 | 72.46 Mn |
| Dec 31, 2022 | 81.35 Mn |
| Sep 30, 2022 | 89.15 Mn |
| Jun 30, 2022 | 97.43 Mn |
| Mar 31, 2022 | 95.38 Mn |
| Dec 31, 2021 | 92.58 Mn |
| Sep 30, 2021 | 63.35 Mn |